help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2003-1430
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
145/3/1175    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, S.-N.
Right arrow Articles by Huang, M.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, S.-N.
Right arrow Articles by Huang, M.-H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Endocrinology Vol. 145, No. 3 1175-1184
Copyright © 2004 by The Endocrine Society

Cilostazol, an Inhibitor of Type 3 Phosphodiesterase, Stimulates Large-Conductance, Calcium-Activated Potassium Channels in Pituitary GH3 Cells and Pheochromocytoma PC12 Cells

Sheng-Nan Wu, Shiuh-Inn Liu and Mei-Han Huang

Institute of Basic Medical Sciences (S.-N.W., M.-H.H.), National Cheng-Kung University Medical College, 701 Tainan, Taiwan; and Department of Surgery (S.-.I.L.), Kaohsiung Veterans General Hospital, 813 Kaohsiung City, Taiwan

Address all correspondence and requests for reprints to: Dr. Sheng-Nan Wu, Institute of Basic Medical Sciences, National Cheng-Kung University Medical College, No. 1, University Road, 701 Tainan, Taiwan. E-mail: snwu{at}mail.ncku.edu.tw.

The effects of cilostazol, a dual inhibitor of type 3 phosphodiesterase and adenosine uptake, on ion currents were investigated in pituitary GH3 cells and pheochromocytoma PC12 cells. In whole-cell configuration, cilostazol (10 µM) reversibly increased the amplitude of Ca2+-activated K+ current [IK(Ca)]. Cilostazol-induced increase in IK(Ca) was suppressed by paxilline (1 µM) but not glibenclamide (10 µM), dequalinium dichloride (10 µM), or ß-bungarotoxin (200 nM). Pretreatment of adenosine deaminase (1 U/ml) or {alpha},ß-methylene-ADP (100 µM) for 5 h did not alter the magnitude of cilostazol-stimulated IK(Ca). Cilostazol (30 µM) slightly suppressed voltage-dependent L-type Ca2+ current. In inside-out configuration, bath application of cilostazol (10 µM) into intracellular surface caused no change in single-channel conductance; however, it did increase the activity of large-conductance Ca2+-activated K+ (BKCa) channels. Cilostazol enhanced the channel activity in a concentration-dependent manner with an EC50 value of 3.5 µM. Cilostazol (10 µM) shifted the activation curve of BKCa channels to less positive membrane potentials. Changes in the kinetic behavior of BKCa channels caused by cilostazol were related to an increase in mean open time and a decrease in mean closed time. Under current-clamp configuration, cilostazol decreased the firing frequency of action potentials. In pheochromocytoma PC12 cells, cilostazol (10 µM) also increased BKCa channel activity. Cilostazol-mediated stimulation of IK(Ca) appeared to be not linked to its inhibition of adenosine uptake or phosphodiesterase. The channel-stimulating properties of cilostazol may, at least in part, contribute to the underlying mechanisms by which it affects neuroendocrine function.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. Fukasawa, H. Nishida, T. Sato, M. Miyazaki, and H. Nakaya
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (Cilostazol), a Phosphodiesterase Type 3 Inhibitor, Reduces Infarct Size via Activation of Mitochondrial Ca2+-Activated K+ Channels in Rabbit Hearts
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 100 - 104.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C.-W. Huang, C.-C. Huang, and S.-N. Wu
Activation by Zonisamide, a Newer Antiepileptic Drug, of Large-Conductance Calcium-Activated Potassium Channel in Differentiated Hippocampal Neuron-Derived H19-7 Cells
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 98 - 106.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society